In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, after nearly three ...
4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...
Despite challenges like high costs and regulatory complexities, Europe's vibrant research ecosystem and EMA's supportive ATMP ...
Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series B funding that the Italian biotech will use to | Amgen Ventures-backed ...
Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.
A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...
Clinical Trials Arena on MSN
Intellia pauses Phase III gene therapy trial after patient hospitalised
A patient dosed in the MAGNITUDE study has suffered a Grade 4 liver transaminases and increased total bilirubin.
On her mother’s instruction, a toddler gives her pink stuffed horse, Snap Snap, a big cuddle. Then, as told, she plants a kiss on his soft fur and, because he’s hungry, feeds him a pretend bowl of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback